From September 15th to 17th, the “7th China Infection and Antimicrobial Therapy Forum” and the “12th National Conference on Infectious Diseases and Antimicrobial Chemotherapy” were held in Shanghai, and industry experts from all over the country gathered together. The aim was to discuss the diagnosis and treatment of clinical micro-organisms and infectious diseases, with more than 1,000 doctors in related fields attended the meeting.
The conference was hosted by the Shanghai Medical Association and supported by the Chinese Medical Association. It was organized by the Shanghai Medical Association Infection and Chemotherapy Branch and the Antibiotic Research Institute of Huashan Hospital of Fudan University. As a grand event in the field of domestic infectious diseases, this forum has established an important multidisciplinary communication platform for improving the diagnosis and treatment of infectious diseases and the rational application of antibacterial drugs in China.
As the exclusive title sponsor of the forum debate, Hansoh Pharma set up a corporate booth to convey the latest developments in the R&D of anti-infective drugs of Hansoh to the participants. The participating experts and doctors highly praised the company's research level in the field of anti-infective drugs. At the same time, the academic debate contest titled by Hansoh Pharma played an active role in stimulating academic thinking and promoting the development of disciplines. The image of Hansoh's strong sense of social responsibility was also widely recognized by the participating experts.
Anti-infective is one of Hansoh's six key therapeutic areas. The company has invested heavily in R&D over the past 20 years to overcome the pathogenesis of infectious diseases, and researched and imitated a batch of medicine with good efficacy and safety profiles. At present, a variety of premium anti-infective drugs such as Zetan (Tigecycline for Injection), Hengjie (Linezolid and Glucose Injection), Hengdan (Cefdinir Capsule), Hengyun (Cefaclor Dispersible Tablets), Meifeng (Cefalexin Extend-release tablets), Hengluo (Cefcapene Pivoxil Hydrochloride Tablets), and Hengte (Roxithromycin Sustained Release Tablets) have been put into market, helping countless patients to return to a healthy life.
In 2014, Hansoh's Category 1.1 innovative drug, Mailingda (Morinidazole and Sodium Chloride Injection), was successfully launched, which provided a new diagnosis and treatment method for the clinical treatment of anaerobic bacteria in China, effectively expanding the choice of drugs for the first-line doctors. In July of this year, the drug was successfully listed into the National Reimbursement Drug List, enabling patients to receive safer and more effective treatments at a lower cost. From imitation to innovation, Hansoh Pharma has made a milestone breakthrough in transformation and upgrading, becoming one of the pioneer companies in the R&D of innovative drugs in China.
